TorreyPines has been developing a new type of migraine drug called Tezampanel, which is a glutamate reception inhibitor. One of the current theories about migraines involves the observation that people experiencing migraines have an excess of an amino acid known as glutamate. Glutamate naturally occurs in the brain and is essential for healthy people, but too much of it can lead to a number of diseases or conditions. Drugs like Tezampanel act to stop a migraine by blocking glutamate in the brain.
It remains unclear what will now happen to Tezampanel in the wake of TorreyPines' financial failure. Perhaps it will be sold to another pharmaceutical company. Hopefully it will not simply fall by the wayside and fade into obscurity.
Addex Pharmaceuticals also has a drug (ADX10059) in development that works on glutamate, so even if Tezampanel is lost, research in this area can be expected to continue.
The End of Tezampanel? Say It Isn't So
TorreyPines Therapeutics to Liquidate
Glutamate: A New Key to Migraine Treatment?
TorreyPine Therapeutics: Tezampanel & NGX426
Addex Starts Phase IIb Trial of ADX10059 for Migraine Prevention
Addex Pharmaceuticals Pipeline
AHS Meeting News: Research on New Medications
Technorati Tags: depression, migraines, chronic illness, health, somebody heal me
Subscribe to the Somebody Heal Me feed:
Subscribe in a reader or subscribe by e-mail.
Content by Diana E. Lee.
DISCLAIMER: Nothing on this site constitutes medical or legal advice. I am a patient who is engaged and educated and enjoys sharing my experiences and news about migraines, pain and depression. Please consult your own health care providers for advice on your unique situation.